Related Experiment Video
Updated: Jun 25, 2025
Single-cell Gene Expression Using Multiplex RT-qPCR to Characterize Heterogeneity of Rare Lymphoid Populations
Published on: January 19, 2017
The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST
Loic Verlingue1, Marine Desevre2, Marie Polito2
1Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France. loic.verlingue@lyon.unicancer.fr.
Background And Purpose:
In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST Plus and MEGAMOST.
Patients/Material And Methods:
MOST, MOST Plus and MEGAMOST comprise 14 cohorts with different targeted agents and immunotherapies.
Results And Interpretation:
PROFILER has recruited 5,991 patients in 10 years, MOST and MOST Plus 875 patients since 2014 and MEGAMOST 172 patients since 2020, and are still ongoing. We provide a description of the local, national and international implications of these initiatives, and we review the results of the sorafenib and olaparib cohorts.
Insights
French academic molecular analysis platforms like PROFILER and personalized medicine trials MOST, MOST Plus, and MEGAMOST are detailed. These initiatives have implications for cancer research and treatment, with ongoing patient recruitment.
Area of Science:
- Oncology
- Genomics
- Clinical Trials
Background:
- Description of French academic molecular analysis platforms.
- Introduction to PROFILER, MOST, MOST Plus, and MEGAMOST initiatives.
Purpose of the Study:
- To detail the structure and scope of French multicentric molecular analysis platforms.
- To present the design and progress of personalized medicine trials.
Main Methods:
- Overview of the PROFILER platform.
- Description of the MOST, MOST Plus, and MEGAMOST trials, comprising 14 cohorts.
- Inclusion of targeted agents and immunotherapies in trial designs.
Main Results:
- PROFILER has recruited 5,991 patients over 10 years.
- MOST and MOST Plus have enrolled 875 patients since 2014.
- MEGAMOST has enrolled 172 patients since 2020, with ongoing recruitment for all trials.
Conclusions:
- These platforms and trials have significant local, national, and international implications.
- Review of results from sorafenib and olaparib cohorts provides insights into treatment efficacy.
- Ongoing patient recruitment highlights the continued importance and expansion of these initiatives.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:02Genomics